Pharmx Technologies Limited · ASX:PHX
Pharmx Technologies — FY2023 Earnings Presentation
20 slides from Pharmx Technologies's earnings presentation, Aug 23, 2023
Slide 1: Corum Group Limited FY23 Results
Corum Group Limited FY23 Results 23 August 2023
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by Corum Group Limited (COO or the results, performance or achievements expressed or implied by the forward- Company or Corum) and has been authorised for release by the Board. It looking statements contained in this document will act
Slide 3: FY23 Operational Highlights
FY23 Operational Highlights Pharmacy Software business sale • Binding agreement to sell the Pharmacy Software business • Consideration of $6.25m o $4.75m upfront at completion o $1.50m deferred 12 months • Potential for earn out payments – 12 month and 24 month anniversary of completion • Completes
Slide 4: FY23 Financial Highlights
FY23 Financial Highlights New initiatives and investment driving revenue growth Financials Continuing Operations Metrics FY23 FY22 vs PCP Revenue $6.1m $5.4m + 14% Underlying EBITDA $1.6m(1) $1.8m(1) (12)% Underlying NPAT $0.4m(1) $0.7m(1) (48)% Underlying operating cashflow, net of R&D tax $1.0m(2)
Slide 5: Profit and Loss
Profit and Loss Revenue growth of 14%, while delivering a strong EBITDA margin of 26% FY23 FY22 Var $ Var % • Underlying results exclude the Health Software business. Revenue 6,127 5,385 742 14% • Revenue growth mainly from underlying Underlying costs (4,561) (3,603) (958) 27% PharmX business, and s
Slide 6: Cashflow
Cashflow Positive operating cashflow continues $'000 FY23 FY22 Var $ Var % Receipts from customers - continuing 6,585 5,359 1,226 23% • Decline in underlying cashflow due to operations investment into the launch of PharmXchange. Statutory Operating Cashflow 10,944 3,281 7,663 234% Add-Back Non-recur
Slide 7: PharmX Technologies Limited
PharmX Technologies Limited PharmX PharmXchange • Dominant EDI gateway for Australian pharmacy market • Innovative B2B Pharmacy Marketplace integrated with • Fast growing NZ business in partnership with Chemist PharmX gateway Warehouse • Sales commission model • High margin, scalable business with h
Slide 8: PharmX: Driving Connectivity
PharmX Driving Connectivity 7.5 21 +19% +16% average highest yoy 71 yoy number of total connections increase in increase in connections number of per total transaction in a suppliers pharmacy connections value pharmacy Long term growth runway 8
Slide 9: PharmX: Drivers of Connectivity
PharmX Drivers of Connectivity • 60 day dispensing – creating a need for efficiency gains • Supplier cost savings – escalating cost to serve • POS vendor relationships and rebates (PharmX independence) Growth Initiatives • Direct to pharmacy marketing • EDMs / Webinars / retail group training • Cont
Slide 10: PharmXchange
PharmXchange The stage is set….. Compelling proposition to both suppliers and pharmacies… 1,800+ 60 175 7,500+ pharmacies suppliers brands products 10
Slide 11: PharmXchange: making it happen
PharmXchange … making it happen • POS integrations with > 40% of the market o Corum Health o Z Software • Independence providing opportunity to partner with all of POS market • Changing ordering behaviour • Webinars, retail pharmacy group contracts, direct to pharmacy marketing • Unique marketing ca
Slide 12: Closing Summary
Closing Summary A positive result for FY23, growth to continue • Repositioned business is a unique, data rich pharmacy industry technology player with operating leverage • Independent, software agnostic service provider to the pharmacy market • Focused management team to drive growth • Long growth r
Slide 13: Questions
Questions
Slide 14: Appendix
Appendix
Slide 15: Corporate Overview
Corporate Overview Corum Group Limited (ASX:COO) at 17 Aug 23 Capital Structure Share Price 4.9cps Shares on Issue (m) 597.4 Market Capitalisation $29.3m Options / Perf Rights (m) 11.9 Enterprise Value (Cash 30/06/23) $16.5m Diluted Issued Capital (m) 609.3 Share Price Performance 6c 8 5c Share pric
Slide 16: Profit & Loss
Profit & Loss Profit & Loss ($'000) FY23 FY22 ∆ PCP Revenue $6,127 $5,385 13.8% Expenses Materials and consumables ($1,210) ($821) 47.4% Employee Benefits ($2,491) ($2,063) 20.7% Marketing ($172) ($101) 70.3% Technology, communication and cloud costs ($421) ($361) 16.6% Legal ($1,262) ($869) 45.2% C
Slide 17: Cashflow
Cashflow Cash flow ($’000) FY23 FY22 Cash flows from operating activities Receipts from customers $13,072 $12,582 Payments to suppliers and employees ($11,915) ($10,839) Interest and other revenue received $109 $29 Proceeds from PharmX court case judgement $8,128 - Research and development incentive
Slide 18: Balance Sheet
Balance Sheet Balance Sheet ($'000) 30 June 2023 - FY23 30 June 22 - FY22 Current assets Cash and cash equivalents $12,806 $5,759 Trade and other receivables $946 $1,085 Inventories - $42 Income tax receivable $1,659 $1,549 Other assets $229 $151 Assets of disposal group classified as held for sale
Slide 19: Share Registry
Share Registry Top holders at 17 August 2023 Rank Name Units % Units 1 LUJETA PTY LTD <MARGARET A/C> 89,480,946 14.98% 2 ARROTEX INVESTMENTS HOLDING 1 PTY LTD 60,000,000 10.04% 3 NATIONAL NOMINEES LIMITED 40,242,512 6.74% 4 MERSAULT PTY LTD <ENGLAND S/F A/C> 26,766,667 4.48% 5 MR DAVID GERALD MANUEL
Slide 20: Corum Group Limited
Corum Group Limited Contact: Investor.Relations@corum.com.au